Triokris™ (Trientine Hydrochloride 250 mg Capsules)

Triokris™ is a generic version of Trientine Hydrochloride 250 mg, developed and manufactured in a USFDA-approved facility by Ikris Pharma Network Pvt. Ltd., India. This medicine is available in India for the management of Wilson’s Disease, a rare genetic disorder that causes toxic copper accumulation in vital organs such as the liver, brain, and eyes.

Triokris binds excess copper and enhances its urinary excretion, helping restore copper balance and prevent long-term organ damage. It is widely recognized as a safe and effective alternative to D-Penicillamine, suitable for long-term therapy.

With our headquarters in India and a global presence spanning Belgium, Hong Kong, and Bulgaria, Ikris Pharma Network Pvt. Ltd. is a leading global pharmaceutical company specializing in Named Patient Import Programs, Rare Disease Medicines, and Global Pharmaceutical Import/Export.
We are known for delivering high-quality medicines to over 100 countries across Europe, the Pacific Region, Latin America, Southeast Asia, Central Asia, the Middle East, and Africa.
We specialize in the global distribution of essential, hard-to-access, and specialty medications, supporting importers, distributors, and wholesalers in critical therapeutic areas like advanced oncology care, Nephrology, Haematology, Cardiology, and infectious disease management.

• Adults (≥13 years): The initial dose is 750 to 1250 mg per day, divided into two, three, or four doses daily.
  
• Children (≤12 years): The initial dose is 500 to 750 mg per day, given in divided doses two to four times daily.
  
• Maximum dose: Up to 2000 mg/day for adults and 1500 mg/day for pediatric patients aged 12 years or under.
  
• Take Trientine Hydrochloride Capsules on an empty stomach, at least one hour before meals or two hours after meals.
  
• Maintain at least a one-hour gap between Triokris and any other medication, food, or milk.
  
• Capsules should be swallowed whole with water — do not open or chew the capsules.
  
• Maintain consistent dosing times each day to ensure steady copper control and effective treatment results.
  

Trientine 250 mg is a proven copper chelator for Wilson’s disease, effective in both hepatic and neurological forms.
In comparative studies, efficacy was similar to D-penicillamine for improvement or stabilization of hepatic and neurological symptoms.
Better tolerability — discontinuation rates were significantly lower with trientine (7.1%) than with penicillamine (28.8%).
Non-inferior maintenance efficacy demonstrated in the CHELAT trial, where trientine maintained copper control equivalent to penicillamine in stable patients.
Well-established long-term safety, making it the preferred alternative in patients intolerant to penicillamine or zinc therapy.

Limited Clinical Experience: Patient experience with Trientine Hydrochloride is limited. Continuous clinical supervision is essential during therapy to monitor safety, response, and potential side effects.
General Precautions: No hypersensitivity seen in patients, but rare asthma or skin reactions reported in industrial exposure. Monitor for allergic or respiratory symptoms.
Accidental Exposure: In case of accidental skin exposure to capsule contents, wash the affected area immediately with water.
Initial Treatment Monitoring: During the first month of therapy, patients should monitor their temperature nightly and promptly report any fever, rash, or skin eruption to a physician.
Free Copper Monitoring: The most reliable indicator of treatment effectiveness is the free copper concentration in serum, calculated as: Total Copper – (Ceruloplasmin × 3). Adequately treated patients typically have less than 10 mcg/mL of free copper in serum.
Urinary Copper Excretion: A 24-hour urinary copper test is recommended every 6–12 months. Urine should be collected in copper-free glassware. A negative copper balance of 0.5–1.0 mg/day indicates effective copper removal.
Iron Deficiency: If iron deficiency develops, a short course of iron supplementation may be prescribed under medical supervision. Iron should not be taken simultaneously with Trientine, as both interfere with each other’s absorption.

Limited Clinical Experience: Patient experience with Trientine Hydrochloride is limited. Continuous clinical supervision is essential during therapy to monitor safety, response, and potential side effects.
General Precautions: No hypersensitivity seen in patients, but rare asthma or skin reactions reported in industrial exposure. Monitor for allergic or respiratory symptoms.
Accidental Exposure: In case of accidental skin exposure to capsule contents, wash the affected area immediately with water.
Initial Treatment Monitoring: During the first month of therapy, patients should monitor their temperature nightly and promptly report any fever, rash, or skin eruption to a physician.
Free Copper Monitoring: The most reliable indicator of treatment effectiveness is the free copper concentration in serum, calculated as: Total Copper – (Ceruloplasmin × 3). Adequately treated patients typically have less than 10 mcg/mL of free copper in serum.
Urinary Copper Excretion: A 24-hour urinary copper test is recommended every 6–12 months. Urine should be collected in copper-free glassware. A negative copper balance of 0.5–1.0 mg/day indicates effective copper removal.
Iron Deficiency: If iron deficiency develops, a short course of iron supplementation may be prescribed under medical supervision. Iron should not be taken simultaneously with Trientine, as both interfere with each other’s absorption.

Limited Clinical Experience: Patient experience with Trientine Hydrochloride is limited. Continuous clinical supervision is essential during therapy to monitor safety, response, and potential side effects.
General Precautions: No hypersensitivity seen in patients, but rare asthma or skin reactions reported in industrial exposure. Monitor for allergic or respiratory symptoms.
Accidental Exposure: In case of accidental skin exposure to capsule contents, wash the affected area immediately with water.
Initial Treatment Monitoring: During the first month of therapy, patients should monitor their temperature nightly and promptly report any fever, rash, or skin eruption to a physician.
Free Copper Monitoring: The most reliable indicator of treatment effectiveness is the free copper concentration in serum, calculated as: Total Copper – (Ceruloplasmin × 3). Adequately treated patients typically have less than 10 mcg/mL of free copper in serum.
Urinary Copper Excretion: A 24-hour urinary copper test is recommended every 6–12 months. Urine should be collected in copper-free glassware. A negative copper balance of 0.5–1.0 mg/day indicates effective copper removal.
Iron Deficiency: If iron deficiency develops, a short course of iron supplementation may be prescribed under medical supervision. Iron should not be taken simultaneously with Trientine, as both interfere with each other’s absorption.